Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Real World Evidence Study to Describe Characteristics and Outcomes in Dutch Patients Admitted to the Hospital With a Factor Xa Inhibitor-associated Bleeding Treated With Andexanet Alfa

NCT05898412 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05898412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05898412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Real World Evidence Study to Describe Characteristics and Outcomes in Dutch Patients Admitted to the Hospital With a Factor Xa Inhibitor-associated Bleeding Treated With Andexanet Alfa
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 6, 2023
Completion date
November 25, 2025
Enrollment
217 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhage